ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Harvey I. Pass
Barbara K. Temeck
Jessica S. Donington
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pass, H. I.
Right arrow Articles by Rosenberg, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pass, H. I.
Right arrow Articles by Rosenberg, S. A.

Ann Thorac Surg 1996;61:1609-1617
© 1996 The Society of Thoracic Surgeons

Original Article: General Thoracic

Isolated Lung Perfusion With Tumor Necrosis Factor for Pulmonary Metastases

Harvey I. Pass, MD, Daphne J. Y. Mew, MD, PhD, Karen C. Kranda, RN, Barbara K. Temeck, MD, Jessica S. Donington, MD, Steven A. Rosenberg, MD, PhD

Thoracic Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Background. A phase I trial was initiated to define the feasibility and safety of single-lung isolation perfusion with tumor necrosis factor-{alpha}, interferon-{gamma}, and moderate hyperthermia for patients with unresectable pulmonary metastases.

Methods. Twenty patients with lung metastases (Ewing's, 2; sarcoma, 8; melanoma, 6; other, 4) were considered for single-lung isolation perfusion with 0.3 to 6.0 mg of tumor necrosis factor-{alpha} and 0.2 mg interferon-{gamma} delivered through an oxygenated pump circuit. Sixteen perfusions were performed in 15 patients (bilateral in 1). Metastases were completely resected (no single-lung isolation perfusion) in 3 patients, 1 patient had extrapulmonary disease, and one single-lung isolation perfusion was aborted for mechanical reasons.

Results. There were no significant changes in systemic arterial blood pressure or cardiac output during perfusion. Systolic pulmonary artery pressure increased with isolation, but returned to pre-single-lung isolation perfusion levels after clamp release. The maximum systemic tumor necrosis factor-{alpha} level was 8 ng/mL, whereas pump-circuit levels ranged from 200 to 10,976 ng/mL. There were no deaths, and the mean hospitalization period was 9 days (range, 5 to 34 days). A short-term (6 to 9 month) unilateral decrease in perfused nodules was noted in 3 patients (melanoma in 1, adenoid cystic carcinoma in 1, renal cell carcinoma in 1).

Conclusions. Future studies using a combination of biologic modifiers, chemotherapy, and hyperthermia should be pursued to define active cytotoxic agents that will preserve underlying pulmonary function.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
T. L. Demmy, G. Tomaszewski, G. K. Dy, S. Yendamuri, C. Nwogu, L. Pendyala, N. Ramnath, and A. A. Adjei
Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results).
Ann. Thorac. Surg., August 1, 2009; 88(2): 385 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Yan, C. Cheng, A. Haouala, T. Krueger, J.-P. Ballini, S. Peters, L. A. Decosterd, I. Letovanec, H.-B. Ris, and S. Andrejevic-Blant
Distribution of Free and Liposomal Doxorubicin After Isolated Lung Perfusion in a Sarcoma Model
Ann. Thorac. Surg., April 1, 2008; 85(4): 1225 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. P. van Putte, M. Grootenboers, W.-J. van Boven, J. M. H. Hendriks, P. E. Y. van Schil, G. Guetens, G. De Boeck, G. Pasterkamp, F. Schramel, and G. Folkerts
Pharmacokinetics of Gemcitabine when Delivered by Selective Pulmonary Artery Perfusion for the Treatment of Lung Cancer
Drug Metab. Dispos., April 1, 2008; 36(4): 676 - 681.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
P. E. Van Schil, J. M. Hendriks, B. P. van Putte, B. A. Stockman, P. R. Lauwers, P. W. ten Broecke, M. J. Grootenboers, and F. M. Schramel
Isolated lung perfusion and related techniques for the treatment of pulmonary metastases
Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 487 - 496.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. Krueger, A. Kuemmerle, S. Andrejevic-Blant, H. Yan, Y. Pan, J.-P. Ballini, W. Klepetko, L. A. Decosterd, R. Stupp, and H.-B. Ris
Antegrade Versus Retrograde Isolated Lung Perfusion: Doxorubicin Uptake and Distribution in a Sarcoma Model
Ann. Thorac. Surg., December 1, 2006; 82(6): 2024 - 2030.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
M. J. Grootenboers, J. Heeren, B. P Van putte, J. M. Hendriks, W. J Van boven, P. E. Van schil, and F. M. Schramel
Isolated lung perfusion for pulmonary metastases, a review and work in progress
Perfusion, September 1, 2006; 21(5): 267 - 276.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. P. van Putte, J. M.H. Hendriks, G. Guetens, G. de Boeck, E. A. de Bruijn, P. E.Y. van Schil, and G. Folkerts
Modified approach of administering cytostatics to the lung: more efficient isolated lung perfusion.
Ann. Thorac. Surg., September 1, 2006; 82(3): 1033 - 1037.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. Krueger, A. Kuemmerle, M. Kosinski, A. Denys, L. Magnusson, R. Stupp, A. B. Delaloye, W. Klepetko, L. Decosterd, H.-B. Ris, et al.
Cytostatic lung perfusion results in heterogeneous spatial regional blood flow and drug distribution: Evaluation of different cytostatic lung perfusion techniques in a porcine model.
J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 304 - 311.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
B. P. v. Putte, A. Huisman, J. M.H. Hendriks, P. E.Y. v. Schil, W. J. v. Boven, F. Schramel, F. Nijkamp, and G. Folkerts
Pulmonary intravascular volume can be used for dose calculation in isolated lung perfusion
Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 594 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. H. Hendriks, M. J. J. H. Grootenboers, F. M. N. H. Schramel, W. J. van Boven, B. Stockman, H. T. M. ter Beek, C. A. Seldenrijk, P. ten Broecke, C. A. J. Knibbe, P. Slee, et al.
Isolated Lung Perfusion With Melphalan for Resectable Lung Metastases: A Phase I Clinical Trial
Ann. Thorac. Surg., December 1, 2004; 78(6): 1919 - 1927.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
U. F.W. Franke, T. Wittwer, M. Lessel, K. Liebing, M. Albert, V. Becker, H. Schubert, and T. Wahlers
Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: I. Influence of perfusion pressure and hyperthermia on functional and morphological lung integrity
Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 792 - 799.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. P. Van Putte, J. M. H. Hendriks, S. Romijn, B. Pauwels, G. De Boeck, G. Guetens, E. De Bruijn, and P. E. Y. Van Schil
Pharmacokinetics after pulmonary artery perfusion with gemcitabine
Ann. Thorac. Surg., October 1, 2003; 76(4): 1036 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
G.-S. Shin, B.-H. Lee, S. Lee, S.-Y. Chung, M. Kim, J. Lim, Y. Kim, H. J. Kwon, C. S. Kang, and K. Han
Monokine Levels in Cancer and Infection
Ann. Clin. Lab. Sci., April 1, 2003; 33(2): 149 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
E. Savier, D. Azoulay, E. Huguet, F. Lokiec, M. Gil-Delgado, and H. Bismuth
Percutaneous Isolated Hepatic Perfusion for Chemotherapy: A Phase 1 Study
Arch Surg, March 1, 2003; 138(3): 325 - 332.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. P. Van Putte, J. M.H. Hendriks, S. Romijn, G. Guetens, G. De Boeck, E. A. De Bruijn, and P. E.Y. Van Schil
Single-pass isolated lung perfusion versus recirculating isolated lung perfusion with melphalan in a rat model
Ann. Thorac. Surg., September 1, 2002; 74(3): 893 - 898.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Schneider, S. Kampfer, C. Loddenkemper, T. Foitzik, and H. J. Buhr
Chemoembolization of the Lung Improves Tumor Control in a Rat Model
Clin. Cancer Res., July 1, 2002; 8(7): 2463 - 2468.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. S. Schrump, S. Zhai, D. M. Nguyen, T. S. Weiser, B. A. Fisher, R. E. Terrill, B. M. Flynn, P. H. Duray, and W. D. Figg
Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques
J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 686 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. Tanaka, Y. Kaneda, T.-S. Li, T. Matsuoka, N. Zempo, and K. Esato
Digitonin enhances the antitumor effect of cisplatin during isolated lung perfusion
Ann. Thorac. Surg., October 1, 2001; 72(4): 1173 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. R. Alexander, S. K. Libutti, D. L. Bartlett, M. Puhlmann, D. L. Fraker, and L. C. Bachenheimer
A Phase I-II Study of Isolated Hepatic Perfusion Using Melphalan with or without Tumor Necrosis Factor for Patients with Ocular Melanoma Metastatic to Liver
Clin. Cancer Res., August 1, 2000; 6(8): 3062 - 3070.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.